Unraveling the Turmoil: Why Biotech Stocks Plummeted and What Investors Should Know
March was a challenging month for early-stage biotech stocks, with notable companies like Biohaven, Recursion Pharmaceuticals, and CRISPR Therapeutics experiencing significant share price declines. Biohaven's drug candidate BHV-7000 underperformed in…